Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AML

Venetoclax, CLAD/LDAC and azacitdine in older AML patientsПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 yearsПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

Venetoclax and azacitidine for AML ineligible for standard inductionПодробнее

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AMLПодробнее

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023Подробнее

Venetoclax and azacitidine in older patients with AMLПодробнее

OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AMLПодробнее

Comparison of venetoclax-based versus non-venetoclax-based treatment regimens in AMLПодробнее

Can Venetoclax plus Azacitidine Help AML Patients Ineligible for Intensive Treatment?Подробнее

Venetoclax and azacitidine for young patients with AMLПодробнее

AML: Optimizing Selection and Use of Venetoclax + AzacitidineПодробнее

Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AMLПодробнее

CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trialПодробнее

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AMLПодробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее

Venetoclax + azacitidine in unfit patients with AMLПодробнее